Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics

Mirum Pharmaceuticals, Inc. - common stock (MIRM): $25.84

0.43 (+1.69%)

POWR Rating

Component Grades














  • Growth is the dimension where MIRM ranks best; there it ranks ahead of 73.56% of US stocks.
  • MIRM's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • MIRM's current lowest rank is in the Quality metric (where it is better than 3.97% of US stocks).

MIRM Stock Summary

  • MIRUM PHARMACEUTICALS INC's stock had its IPO on July 18, 2019, making it an older stock than just 14.35% of US equities in our set.
  • MIRM's price/sales ratio is 21.42; that's higher than the P/S ratio of 93.9% of US stocks.
  • Revenue growth over the past 12 months for MIRUM PHARMACEUTICALS INC comes in at 250.13%, a number that bests 96.13% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MIRUM PHARMACEUTICALS INC are VLN, FOLD, TARS, API, and PXLW.
  • Visit MIRM's SEC page to see the company's official filings. To visit the company's web site, go to mirumpharma.com.

MIRM Valuation Summary

  • MIRM's EV/EBIT ratio is -19.1; this is 276.85% lower than that of the median Healthcare stock.
  • MIRM's EV/EBIT ratio has moved down 12.2 over the prior 38 months.

Below are key valuation metrics over time for MIRM.

Stock Date P/S P/B P/E EV/EBIT
MIRM 2022-09-01 21.6 7.5 -15.7 -19.1
MIRM 2022-08-31 21.2 7.4 -15.4 -18.8
MIRM 2022-08-30 20.3 7.1 -14.7 -18.0
MIRM 2022-08-29 21.5 7.5 -15.6 -19.0
MIRM 2022-08-26 21.3 7.4 -15.4 -18.8
MIRM 2022-08-25 21.9 7.6 -15.9 -19.4

MIRM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MIRM has a Quality Grade of C, ranking ahead of 49.16% of graded US stocks.
  • MIRM's asset turnover comes in at 0.052 -- ranking 319th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MIRM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.052 1 -0.949
2021-03-31 0.000 NA -1.229
2020-12-31 0.000 NA -1.146
2020-09-30 0.000 NA -0.934
2020-06-30 0.000 NA -0.781
2020-03-31 0.000 NA -0.694

MIRM Price Target

For more insight on analysts targets of MIRM, see our MIRM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.33 Average Broker Recommendation 1.29 (Strong Buy)

MIRM Stock Price Chart Interactive Chart >

Price chart for MIRM

MIRM Price/Volume Stats

Current price $25.84 52-week high $30.55
Prev. close $25.41 52-week low $12.82
Day low $24.37 Volume 35,310
Day high $26.14 Avg. volume 225,770
50-day MA $24.36 Dividend yield N/A
200-day MA $21.57 Market Cap 949.49M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

MIRM Latest News Stream

Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream

Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about MIRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has caught the attention of institutional investors who hold a sizeable 46% stake

If you want to know who really controls Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ), then you'll have to look at the...

Yahoo | September 4, 2022

Hedge Funds Were Right About These 10 Small-Cap Stocks

In this article, we will discuss how hedge funds were right about these 10 small-cap stocks. To skip our detailed analysis of well-performing industries in 2022, go directly and see Hedge Funds Were Right About These 5 Small-Cap Stocks. With the threat of a global recession looming over their heads, investors are having a tough […]

Yahoo | September 2, 2022

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif., August 30, 2022--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

Yahoo | August 30, 2022

CyberOptics and Mirum Pharmaceuticals Stock See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Yahoo | August 26, 2022

Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

FOSTER CITY, Calif., August 12, 2022--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 521,739 shares, at a price to t

Yahoo | August 12, 2022

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo -6.00%
3-mo 20.97%
6-mo 18.80%
1-year 44.36%
3-year 149.90%
5-year N/A
YTD 62.01%
2021 -8.65%
2020 -28.79%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6976 seconds.